Drug Utilization Review Board
Minutes Draft

Name of Meeting:	Drug Utilization Review Board
Date of Meeting:	March 9, 2023
Length of Meeting:	2 hours and 20 minutes
Location of Meeting:	DMAS Board Room 102

Members Present:
John Morgan, MD, Acting Chief Medical Officer, Chair
Rachel Cain, PharmD
Elizabeth Gaughan, MD
Kristi Fowler, RPh
Melissa Chouinard, MD
Wendy Nash, PharmD
Denise Lowe, PharmD
Michele Thomas, PharmD

Members Not Present:
Kathryn Reid, PhD
Seth Brant, MD
Matthew Estes, PharmD
Denese Gomes, NP

DMAS Attendees:
MaryAnn McNeil, RPh, Pharmacy Manager
JoeMichael Fusco, PharmD, MCO Pharmacy Compliance Manager
Kiara Jasper, MHA, CPhT, Pharmacy Systems Administrator

Contractors:
Debbie Moody, RPh, Director, Clinical Account Services, Magellan Rx Management
Nancy Eldin, PharmD, Pharmacist Account Executive, Magellan Rx Management
Jeni Hodzic, CPhT, Senior Account Management Specialist, Magellan Rx Management

Visitors:
Brad Kalkwarf
Caroline Faber
Heidi Dix
John Minneci
Katherine Klem
Keri Smith

DRAFT

Laurie Mauthe
Lori Stalker
Scott Burns
Scott Castro
Wallene Bullard

Call to Order and Introductions

Dr. John Morgan welcomed and thanked everyone for attending the DUR meeting.

Dr. Morgan called the meeting to order at 1:00 pm.

Minutes – September 8, 2022

Kristi Fowler motioned to approve the September 8, 2022 meeting minutes as submitted. Dr. Melissa Chouinard seconded the motion.

By-Laws Review

Dr. Rachel Cain gave an update on the DUR By-Laws. The Office of the Attorney General did review the DUR By-Laws and provided their updates. Voting on the DUR By-Laws will occur at the next DUR Board meeting in June 2023.

New Drugs

The DUR Board reviewed Hyftor™ (sirolimus topical gel), Lytgobi® (futibatinib) and Rezlidhia™ (olutasidenib). The Impact Reports and the report for the utilization of these 3 new DUR drugs for FFS and MCOs were reviewed.

The DUR Board discussed the service authorization (SA) criteria for Hyftor™. The DUR Board members were interested in knowing if there are any claims for this product as a compound and the cost. After much discussion by the board, Dr. Michele Thomas motioned to accept the SA criteria with the following changes: question number 5 will be updated to state “Has the prescriber counseled the member on possible adverse effects (e.g., hypersensitivity reactions, serious infections, lymphoma and other malignancies, interstitial lung disease/non-infectious pneumonitis), including counseling male members that Hyftor may impair fertility?”. Dr. Cain seconded the motion.

The DUR Board reviewed the current SA class criteria for Oral Oncology – Hematologic Cancers and Other Neoplasm Drugs. After discussion by the board, Dr. Morgan motioned to accept the SA criteria with the following new updates: add the new drug Rezlidhia to the SA criteria along with the FDA approved indications and minimum age, add new FDA approved indication to Brukinsa (treatment of adult patients with chronic

lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)), and add a new question (question number 3) under the initial approval section stating “Has the prescriber counseled the member on adverse effects of therapy?”. Dr. Thomas seconded the motion.

The DUR Board reviewed the new SA class criteria for Oral Oncology – Other Cancer Drugs. The new criteria combines all the other cancer oral oncology drugs to create one SA criteria for the entire class. This new SA form will eliminate the single SA criteria forms for individual other cancer oral oncology drugs. The DUR Board also reviewed the utilization of these other cancer oral oncology drugs for FFS. Dr. Morgan motioned to accept the SA criteria with the following new update: add a new question (question number 3) under the initial approval section stating, “Has the prescriber counseled the member on adverse effects of therapy?”. Dr. Thomas seconded the motion.

Dr. Cain motioned to add a new question under the initial approval section for all the Oral Oncology Class Criteria (which includes Lung Cancer and Other Neoplasm Drugs and Renal Cell Carcinoma and Other Neoplasm Drugs) stating, “Has the prescriber counseled the member on adverse effects of therapy?”. Dr. Thomas seconded the motion.

MRx Pipeline and DUR Quarterly Newsletter- The October 2022 and January 2023 MRx Pipeline Reports and the September2022 and December 2022 DUR Quarterly Newsletters were available on the DUR Webportal for review.

Topics for Discussion

Concurrent Use of Opioids and Benzodiazepines – The DUR Board reviewed Concurrent Use of Opioids and Benzodiazepines reports for FFS and MCOs. There was an interest around why MCO 6 has a higher rate base per 10,000 members compared to the other MCOs. This will be investigated further.

Concurrent Use of Opioids and Antipsychotics – The DUR Board reviewed Concurrent Use of Opioids and Antipsychotics reports for FFS and MCOs. A request was made to see if there were any overlaps in therapy for members on opioids, benzodiazepines, and antipsychotics.

Antipsychotic Medications in Children – The DUR Board reviewed Antipsychotic Medications in Children reports for FFS and MCOs.

Antidepressant Medications in Children – The DUR Board reviewed Antidepressant Medications in Children reports for FFS and MCOs. There was discussion around

suicidal ideations in the pediatric population and questions on how that is monitored and managed. Dr. Cain attends all the MCOs DUR Board meetings where this is also a topic of discussion. A request was made for a report looking at unique pediatric members with the diagnosis of suicidal ideation for FFS and MCOs. DMAS will follow-up with Behavioral Health.

Mood Stabilizer Medications in Children – The DUR Board reviewed Mood Stabilizer Medications in Children reports for FFS and MCOs. A request was made to see if there were any overlaps in therapy for pediatric members on antipsychotics, antidepressants, and mood stabilizers.

Reports

ProDUR

The DUR Board reviewed the ProDUR reports.

RetroDUR

I. Recent RetroDUR Activity

The DUR Board reviewed the Recent RetroDUR Activity reports.

MaryAnn McNeil reviewed the importance for providers to be compliant with the 21st Century Cures Act and being enrolled in Virginia Medicaid to be able to continue prescribing to Virginia Medicaid members.

DMAS will be sending another letter in March 2023 to inform prescribers that they must be enrolled as a Virginia Medicaid provider in order to prescribe medications to Virginia Medicaid members.

II. RetroDUR Criteria Estimates

The DUR Board reviewed the Criteria Exception Estimates Reports. The reports were broken down to the Top 40 Criteria Exception Estimates by Members and the Top 40 Criteria Exception Estimates by Total Payment Amount for Fee-For-Service (FFS) and each individual Managed Care Organization (MCO) plan. A request was made in reference to looking at anticholinergic load in members with dysphagia, constipation, ileus, small bowel obstruction, urinary retention or falls in their diagnosis history.

Utilization Analysis

The DUR Board reviewed the Utilization Analysis reports. These reports have been updated to exclude the medical claims and only include pharmacy claims.

Next DUR Meeting

June 8, 2023

Dr. Morgan motioned to adjourn the meeting. Dr. Thomas seconded the motion. Meeting adjourned at 3:20 pm.